Business
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD) THE WOODLANDS, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lexicon
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD)\nTHE WOODLANDS, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective effects of sotagliflozin in patients with diabetic kidney disease (DKD). Data will be presented at Kidney Week 2024, the annual meeting of the American Society of Nephrology in San Diego, California. Previous analyses of the SCORED trial have shown that sotagliflozin, a dual SGLT1 & 2 inhibitor, reduced the risk of kidney and cardiorenal composite endpoints in patients with type 2 diabetes (T2D) and diabetic kidney disease (DKD). The objective of this new post hoc analysis of SCORED was to evaluate the effect of sotagliflozin versus placebo on Estimated Glomerular Filtration Rate (eGFR) slope, and the impact of baseline kidney function and glycemia. The eGFR slope assessment is widely used as a surrogate endpoint in cardiovascular and chronic kidney disease trials. Details for the presentation are as follows: “Effect of sotagliflozin on eGFR slope by baseline kidney function and glycemic control” – a moderated poster presentation, Friday, October 25, 10:00a.m.PT, 4:00-5:00p.m, Exhibit Hall, San Diego Convention Center, presented by Vikas S. Sridhar, M.D., University of Toronto, Ontario Within the entire cohort of 10,574 participants, a placebo-adjusted acute decline in eGFR of -2.59 ml/min/1.73m2/year (95% CI -2.88, -2.30; p","length":2179,"tagName":"div"}]